Dr. Roy becomes Scientific Director of the University Institute of Hemato-oncology and Cellular Therapy

Dr. Denis Claude Roy, Scientific Director of the Hôpital Maisonneuve-Rosemont’s University Institute of Hemato-Oncology and Cellular Therapy.

Dr. Denis Claude Roy has been appointed Scientific Director of the Hôpital Maisonneuve-Rosemont’s University Institute of Hemato-Oncology and Cellular Therapy.

When the HMR became an institute

In October 2019, Hôpital Maisonneuve-Rosemont (HMR) was recognized as a University Institute in Hemato-Oncology and Cellular Therapy by the Ministère de l’Économie et de l’Innovation. A director had yet to be appointed to head this new entity. It is now done.

A well-deserved appointment

The appointment of Dr. Denis Claude Roy, is well-deserved for this hematologist by training and internationally recognized researcher and clinician who has devoted his entire career to of oncology treatments, cell therapy and gene therapy.

Through his work, Dr. Roy is reprogramming the lives of patients at the HMR and elsewhere. His achievements and his ability to bring people together have greatly contributed to the advancement of knowledge and the international standing of Quebec researchers, particularly in the fields of cell therapy and regenerative medicine.

Fully committed to collaboration and cell therapy

Until recently, Dr. Roy was Director of Research at the CIUSSS de l’Est-de-l’Île-de Montréal. He worked closely with the Université de Montréal and its Faculty of Medicine where he teaches,

Director of the first cell therapy laboratory at the HMR for several years, he was, the driving force behind the construction of the Centre of Excellence for Cellular Therapy (CETC) in 2011, which was funded in part by the Foundation. His ever-increasing involvement in the promotion of stem cell treatments led him to found and become the Scientific Director of the Canadian Regenerative Medicine and Cell Therapy Network (CellCAN), where he harnesses knowledge and encourages all Canadian stakeholders to share their know-how and knowledge.

In 2016, he becomes one of the founders of the Center for Commercialization of Cancer Immunotherapy (C3i), which has for mission to accelerate the discovery, deployment and accessibility of cancer immunotherapy treatments.

An ambitious mission

The tasks that await Dr. Roy are commensurate with his talents. As Director of the Institute, he will be responsible for the planning and evaluation of professional, clinical, research and teaching activities for all aspects of hemato-oncology and cell therapy. He will also:

• be the Director of the Centre of Excellence for Cellular Therapy;
• promote clinical activities in hemato-oncology and cell therapy;
• develop research, teaching and knowledge sharing in the field;
• establish links with the Quebec hemato-oncology and cell therapy community.

The great family of the Foundation warmly congratulates him and wishes him every success in taking up this new challenge.